DEXA

RadNet and JVS SoCal Create ImagingWorks®, an Innovative Partnership to Launch Career Training Programs for Medical Imaging

Retrieved on: 
Thursday, February 15, 2024

(RadNet’s President and Chief Executive Officer), are helping close the opportunity gap in a specialized field that equips students for well-paying, meaningful careers in medical imaging.

Key Points: 
  • (RadNet’s President and Chief Executive Officer), are helping close the opportunity gap in a specialized field that equips students for well-paying, meaningful careers in medical imaging.
  • We are proud to partner with Karen and Howard Berger and RadNet on this special initiative,” said JVS SoCal CEO Jeff Carr.
  • “RadNet has been a leading employer-partner of JVS SoCal, especially in our CareerWork$ Medical® program, having hired dozens of graduates since 2019.
  • Through the new ImagingWorks® partnership, RadNet continues its legacy of community involvement and social responsibility,” concluded Mr. Carr.

Aurora Spine’s Second Patent Related to DEXA Technology™ Patient-Matched Implant Technology Issued by the United States Patent Office

Retrieved on: 
Monday, February 5, 2024

Aurora Spine’s first-of-its kind DEXA Technology™ is designed to match a patient’s bone density, promote bone in-growth while maintaining the biomechanical structure and bone support.

Key Points: 
  • Aurora Spine’s first-of-its kind DEXA Technology™ is designed to match a patient’s bone density, promote bone in-growth while maintaining the biomechanical structure and bone support.
  • Aurora Spine’s DEXA Technology™ is part of the company's advanced portfolio representing the future of Spinal and Orthopedic implants.
  • Following fundamental principles of patent focused innovation, DEXA Technology™ was logically created and patented to combine the essential design benefits of conventional machining and additive implant manufacturing.
  • The proprietary engineering behind our DEXA Technology™ is advancing the science of implant technology, and ultimately helping improve patient fusion rates and overall clinical outcomes.

Northwell Opens $52M Cancer Center, Multispecialty Practice in Queens

Retrieved on: 
Tuesday, November 28, 2023

As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.

Key Points: 
  • As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.
  • Northwell treats about 19,000 New Yorkers with cancer each year, more than any other cancer provider in the state.
  • “We’re excited to open a new outpatient cancer center in the heart of Queens to deliver the best cancer care close to where people live,” said Richard Barakat, MD , physician-in-chief and executive director of the Northwell Health Cancer Institute.
  • “Northwell is uniquely positioned to care for patients in Queens – one of the most diverse places in the country.

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasi

Retrieved on: 
Wednesday, October 4, 2023

MIAMI, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, breast cancer and for viral induced ARDS, today announced that the Company will advance its proprietary novel agent, enobosarm, a selective androgen receptor modulator (SARM), into a Phase 2b clinical trial in combination with weight-loss GLP-1 drugs, Ozempic (semaglutide), Wegovy (semaglutide), or Mounjaro (tirzepatide) to evaluate the efficacy and the safety of enobosarm to further increase fat loss while preventing the significant muscle wasting that occurs with weight-loss GLP-1 drugs.

Key Points: 
  • Specifically, enobosarm therapy could augment the preferential loss of fat mass while preventing the loss of critical muscle mass and bone mineral density.
  • Enobosarm treatment could also preserve or improve muscle strength and physical function in older adults being treated with a weight loss drug.
  • The primary endpoint of the study will be change in total lean body mass (muscle) from baseline to 4 months.
  • Key secondary endpoints will be change from baseline to 4 months in total fat mass, insulin resistance (HOMA-IR), and body weight.

Studies Show GLP-1 Weight-Loss Drugs Leading to Loss of Critical Lean Mass

Retrieved on: 
Monday, October 2, 2023

AUSTIN, Texas, Oct. 2, 2023 /PRNewswire/ -- BodySpec, the leader in advanced mobile body composition scans, warns that a significant proportion of the weight loss seen with GLP-1 drugs, such as Ozempic, Wegovy, and Mounjaro, may be lean tissue. While these drugs have been praised for their ability to help people drop weight quickly, it is important to understand the potential risks associated with this rapid weight loss and the ways to mitigate risks with regular body composition scans during treatment.

Key Points: 
  • Recent studies show up to 40% of mass lost during GLP-1 treatment was lean mass, leading to unintended consequences.
  • In another study of 178 patients from the SUSTAIN 8 trial on semaglutide, the average proportion of lean mass loss was nearly identical at 40% (1).
  • Additionally, losing lean mass can make it more difficult to maintain weight loss over the long term (2).
  • It is critical to monitor body composition with a DEXA scan to ensure that patients are not being set up for failure by losing lean mass.

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

Retrieved on: 
Tuesday, September 26, 2023

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive interim safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE, pseudoxanthoma elasticum).

Key Points: 
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.
  • Exploratory biomarker data were collected throughout the study to provide evidence of the potential for disease modification with ongoing treatment with INZ-701.
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • PK properties were consistent with those observed in the Phase 1/2 clinical trial in adults with ENPP1 Deficiency.

Global DEXA Market Poised for Robust Growth, Projected to Reach $307.8 Million by 2028

Retrieved on: 
Thursday, September 21, 2023

Hospitals and clinics are expected to remain the largest segment due to the increasing demand for DEXA machines to scan and identify disorders like osteoporosis.

Key Points: 
  • Hospitals and clinics are expected to remain the largest segment due to the increasing demand for DEXA machines to scan and identify disorders like osteoporosis.
  • Features of the DEXA Market Report:
    Market size estimates in terms of value.
  • Key Questions Answered by the Report:
    What are the high-growth opportunities in the global DEXA market by product type, application, and region?
  • What are the emerging trends and changing customer demands in the DEXA market?

Aurora Spine Corporation Announces Second Quarter Fiscal 2023 Financial Results

Retrieved on: 
Wednesday, August 23, 2023

CARLSBAD, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the financial results for its second quarter fiscal 2023 ended June 30, 2023. All figures are in U.S. dollars.

Key Points: 
  • Management to host conference call for investors in coming week, details to follow -
    CARLSBAD, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the financial results for its second quarter fiscal 2023 ended June 30, 2023.
  • Total operating expenses were $2.514 million for the second quarter of 2023, compared to $2.368 million in the second quarter of 2022.
  • Net loss was $(0.482) million for the second quarter of 2023, compared to the second quarter of 2022 with a loss of $(0.160) million.
  • Basic and diluted net (loss) income per share was $(0.01) per share in the second quarter of 2023 and $(0.00) per share for the second quarter of 2022.

89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 9, 2023

SAN FRANCISCO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • The data were simultaneously presented in a late-breaking oral session at the EASL Congress 2023 in Vienna, Austria and were also selected for inclusion in the Best of EASL Congress summary.
  • The Company intends to meet with the U.S. Food and Drug Administration in the second half of 2023 and to pursue European Union scientific advice in parallel.
  • As of June 30, 2023, 89bio had cash, cash equivalents and short-term available-for-sale securities totaling $478.0 million.
  • 89bio reported a net loss of $38.4 million for the three months ended June 30, 2023, compared to a net loss of $25.1 million for the three months ended June 30, 2022.

Aurora Spine Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Retrieved on: 
Wednesday, June 28, 2023

Carlsbad, Calif, June 28, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that the first patient has been enrolled for its multicenter study of DEXA-CTM Cervical Interbody System.

Key Points: 
  • Carlsbad, Calif, June 28, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that the first patient has been enrolled for its multicenter study of DEXA-CTM Cervical Interbody System.
  • The commencement of the enrollment of patients indicates that the company has received all necessary approvals to launch the study, which will initially include data from 40 single level and 40 multiple level subjects.
  • Mr. Trent Northcutt, Aurora’s President, CEO and co-founder, stated, "The launch of the study is exciting news for Aurora and its DEXA platform technology.
  • The DEXA-C system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s).